Bionexus Gene La (BGLC) Total Assets by Year
Bionexus Gene La closed fiscal year 2025 with $9.3M in total assets, $638K in total liabilities and $8.6M in shareholder equity. This represents a decrease of 11.3% from the prior fiscal year. The table below carries 8 fiscal years, from 2018 to 2025, and the quarters Bionexus Gene La has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BGLC Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.3M-11.3% | $10.4M-8.5% | $11.4M+30.4% | $8.7M-8.7% | $9.6M-5.3% | $10.1M+721.6% | $1.2M-25.5% | $1.7M |
| Total Liabilities | $638K-69.8% | $2.1M+21.2% | $1.7M-16.1% | $2.1M-13.3% | $2.4M-30.7% | $3.5M+3071.7% | $109K-16.5% | $130K |
| Total Equity | $8.6M+3.5% | $8.3M-13.8% | $9.7M+44.9% | $6.7M-7.2% | $7.2M+7.8% | $6.7M+493.6% | $1.1M-26.3% | $1.5M |
BGLC Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.7M-7.4% | $9.0M-4.6% | $9.3M-11.3% | $7.6M-30.7% | $9.4M-15.4% | $9.5M-15.1% | $10.4M-8.5% | $11.0M-4.1% | $11.1M+41.0% | $11.2M+36.3% | $11.4M+30.4% | $11.5M+47.0% |
| Total Liabilities | $948K-50.1% | $947K-44.6% | $638K-69.8% | $805K-49.9% | $1.9M+19.1% | $1.7M-6.0% | $2.1M+21.2% | $1.6M-9.6% | $1.6M-17.6% | $1.8M+11.5% | $1.7M-16.1% | $1.8M+29.3% |
| Total Equity | $7.8M+3.4% | $8.1M+4.1% | $8.6M+3.5% | $6.8M-27.4% | $7.5M-21.2% | $7.8M-16.8% | $8.3M-13.8% | $9.4M+0.8% | $9.5M+70.7% | $9.3M+51.1% | $9.7M+44.9% | $9.3M+45.0% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Bionexus Gene La financials
Frequently Asked Questions
What was Bionexus Gene La's total assets in fiscal year 2025?
Bionexus Gene La closed fiscal year 2025 with $9.3M in total assets, $638K in total liabilities and $8.6M in shareholder equity.
How fast is Bionexus Gene La's total assets growing?
Bionexus Gene La (BGLC) total assets fell by 11.3% year over year, from $10.4M to $9.3M in fiscal year 2025.
How has Bionexus Gene La's total assets changed over the years?
Across the 8 fiscal years this page covers, Bionexus Gene La (BGLC) total assets went from $1.7M in fiscal year 2018 to $9.3M in fiscal year 2025.
What was Bionexus Gene La's total assets in the most recent quarter?
Bionexus Gene La (BGLC) reported $8.7M in total assets in Q2 2026. This represents a decrease of 7.4% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Bionexus Gene La (BGLC) reported on that line in every period on record.